Published on Wed Jun 02 2021

Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine.

Ori Snapiri, Chen Rosenberg Danziger, Nina Shirman, Avichai Weissbach, Alexander Lowenthal, Itay Ayalon, Dganit Adam, Havatzelet Yarden-Bilavsky, Efraim Bilavsky

BNT162b2 is approved for the vaccination of adolescents over 16 years of age. Systemic adverse events were scarce. The aim of the current study is to raise awareness for potential adverse reactions.

1
48
40
Abstract

Vaccines are paramount in the effort to end the coronavirus disease 2019 global epidemic. BNT162b2 is approved for the vaccination of adolescents over 16 years of age. Systemic adverse events were scarce though the pretested cohort of this age group was relatively small. The aim of the current study is to raise awareness for potential adverse reactions.